Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum

Pérez-Soler, Román, Delord, Jean Pierre, Halpern, Allan, Kelly, Karen, Krueger, James, Sureda, Bartomeu Massutí, von Pawel, Joachim, Temel, Jennifer, Siena, Salvatore, Soulières, Denis, Saltz, Leonard, Leyden, James·2005·The Oncologist

Abstract

Learning Objectives: After completing this course, the reader will be able to: Describe the clinical and pathological characteristics of the cutaneous rash secondary to anti-EGFR therapy.Explain the prognostic implications of the cutaneous rash secondary to anti-EGFR therapy.Discuss the treatment of the cutaneous rash secondary to anti-EGFR therapy. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Skin rash associated with HER1/epidermal growth factor receptor (EGFR) inhibitors is common. The lack of clinical and patient guidance for this often chronic and sometimes distressing side effect makes rash management and etiology investigation high priorities. To address this, oncologists and dermatologists with experience with HER1/EGFR inhibitors attended the HER1/EGFR Inhibitor Rash Management Forum. Recommendations include continued analysis of the correlation between rash and clinical outcome and improving the accuracy and reproducibility of terminology and grading systems. Because acne vulgaris has a unique pathology, and the pathology and etiology of rash are unclear yet distinct from acne vulgaris, using such terms as acne, acne-like, or acneiform should be avoided. Until there is a specific dermatological definition, rash is best described using phenotypic terms for its appearance and location. It is currently unknown which agents are best for treating rash. Clinical trials of rash treatments are urgently required, and suggestions for agents to consider are made based on current knowledge. The effect of dose reduction or interruption on rash should also be investigated. Secondarily infected rash may be more frequent than has been previously recognized, and some investigators favor empiric use of an oral antibiotic if this appears to be the case. Suggestions for patients include makeup to camouflage the rash and an emollient to prevent and alleviate skin dryness. The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.10-5-345

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 275

Metadata

Authors
Pérez-Soler, R., Delord, J. P., Halpern, A., Kelly, K., Krueger, J., Sureda, B. M., von Pawel, J., Temel, J., Siena, S., Soulières, D., Saltz, L., & Leyden, J.
Venue
The Oncologist
Published
2005-05-01
Volume
10
Issue
5
Pages
345-356
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2151979638
Cited by
275
References
28
FWCI
31.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. https://app.cochat.ai/papers/10.1634/theoncologist.10-5-345
The paper
Pérez-Soler, R., Delord, J. P., Halpern, A., Kelly, K., Krueger, J., Sureda, B. M., von Pawel, J., Temel, J., Siena, S., Soulières, D., Saltz, L., & Leyden, J. (2005). HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. The Oncologist. https://doi.org/10.1634/theoncologist.10-5-345

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.